Cyrille Tupin
Chief Executive Officer chez ABIONYX PHARMA
Fortune : 2 M $ au 31/03/2024
Provenance du réseau au premier degré de Cyrille Tupin
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 23 | |
Cerenis Therapeutics, Inc.
 Cerenis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cerenis Therapeutics, Inc. discovers, develops and commercializes drugs for the treatment of cardiovascular and metabolic diseases. It focuses on discovery, development, and commercialization of HDL therapies. Cerenis Therapeutics is located in Ann Arbor, MI.
5
| Subsidiary | Pharmaceuticals: Major | 5 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Cyrille Tupin via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| MORGAN STANLEY | Investment Managers | Corporate Officer/Principal | |
| ESPERION THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Operating Officer Chief Tech/Sci/R&D Officer Chief Operating Officer Corporate Officer/Principal | |
| IRONWOOD PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Calliditas Therapeutics Suisse SA
 Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Generic | Director/Board Member | |
| OXFORD BIOMEDICA PLC | Biotechnology | Director/Board Member | |
Dr. Reddy's Research & Development BV
 Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
| Yale University | College/University | Graduate Degree Doctorate Degree | |
| University of Michigan | College/University | Masters Business Admin Corporate Officer/Principal | |
| University of Mumbai | College/University | Doctorate Degree | |
| INNATE PHARMA | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| ABLYNX | Biotechnology | Director/Board Member Director/Board Member | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member | |
| Université de Bordeaux | College/University | Doctorate Degree Undergraduate Degree | |
| Gujarat University | College/University | Undergraduate Degree | |
| ESSEC Business School | College/University | Undergraduate Degree Undergraduate Degree | |
| Université Toulouse III - Paul Sabatier | College/University | Doctorate Degree | |
| Parke, Davis & Co. LLC | Corporate Officer/Principal Corporate Officer/Principal | ||
| Weill Cornell Medical College | College/University | Director/Board Member Corporate Officer/Principal | |
| Serono France SA | Chairman | ||
| ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member | |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| Stephen M. Ross School of Business | College/University | Masters Business Admin Masters Business Admin | |
STJ Advisors LLP
 STJ Advisors LLP Investment ManagersFinance STJ Advisors LLP provides capital markets advisory services. The private company is based in London, UK and has subsidiaries in Hong Kong. The British company was founded in 2008 by John James Moore St. John. | Investment Managers | Corporate Officer/Principal | |
| BIOTALYS NV | Chemicals: Agricultural | Director/Board Member Director/Board Member | |
MedDay Pharmaceuticals SAS
 MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Biotechnology | Chief Executive Officer Chief Executive Officer | |
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
CMR Surgical Ltd.
 CMR Surgical Ltd. Medical SpecialtiesHealth Technology CMR Surgical Ltd. develops universal robotic system for minimal access surgery. The firm is presently evaluating the ability of the versius system to perform upper GI, gynaecological, colorectal and renal surgery in cadaveric trials. The company was founded by Martin Frost and Mark Slack in January 2014 and is headquartered in Cambridge, the United Kingdom. | Medical Specialties | Director/Board Member | |
| Creabilis SA | Director/Board Member | ||
AL-S Pharma AG
 AL-S Pharma AG Pharmaceuticals: MajorHealth Technology AL-S Pharma AG engages in the development and marketing of pharmaceutical products. The company was founded by Michael Salzmann on September 19, 2016 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
| GENKYOTEX SA. | Pharmaceuticals: Major | Director/Board Member | |
Optina Diagnostics, Inc.
 Optina Diagnostics, Inc. Medical SpecialtiesHealth Technology Optina Diagnostics, Inc. manufactures retinal diagnostic imaging devices to detect alzheimer's diseases. The company is headquartered in Montréal, Canada. | Medical Specialties | Director/Board Member | |
DNA Script SAS
 DNA Script SAS Medical SpecialtiesHealth Technology DNA Script engages in the provision of research and development in biotechnology. It manufactures synthetic deoxyribonucleic acid using enzymatic technology. The company was founded by Thomas Ybert, Sylvain Gariel and Xavier Godron in 2014 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member | |
Kymab Group Ltd.
 Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Pharmaceuticals: Major | Director/Board Member | |
Noema Pharma AG
 Noema Pharma AG BiotechnologyHealth Technology Noema Pharma AG is a biotechnology company, which engages in the development of orphan neurological disorder therapies. It focuses on understanding and meeting patient needs using novel therapies. The company was founded by Luigi Costa and George Garibaldi and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
| Alizé Pharma SARL | Director/Board Member | ||
Moonlake Immunotherapeutics AG
 Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The private company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | Pharmaceuticals: Major | Director/Board Member | |
| MOONLAKE IMMUNOTHERAPEUTICS | Pharmaceuticals: Major | Director/Board Member | |
GLWL Research, Inc.
 GLWL Research, Inc. Medical/Nursing ServicesHealth Services GLWL Research, Inc. is a medical research laboratory. It develops and proofs compounds for treatment of diabetes where it has developed an investigational compound known as GLWL-01 to treat type-2 diabetes. The company is headquartered in Montreal, Canada. | Medical/Nursing Services | Director/Board Member | |
Esperas Pharma Inc.
 Esperas Pharma Inc. Pharmaceuticals: MajorHealth Technology Esperas Pharma, Inc. manufactures and develops pharmaceutical products. The firm is created to develop one compound to proof-of-concept. It plans to develop, to proof-of-concept, a compound originally discovered through one of Lilly’s research and development programs, with the potential to treat certain types of cancers including triple negative breast cancer. The company was founded in 2015 and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member |
Statistiques
Internationale
| Etats-Unis | 12 |
| France | 11 |
| Royaume-Uni | 8 |
| Suisse | 7 |
| Canada | 6 |
Sectorielle
| Health Technology | 33 |
| Consumer Services | 10 |
| Finance | 4 |
| Process Industries | 2 |
| Health Services | 2 |
Opérationnelle
| Director/Board Member | 169 |
| Corporate Officer/Principal | 62 |
| Independent Dir/Board Member | 33 |
| Chairman | 28 |
| Chief Executive Officer | 21 |
Relations les plus connectées
| Insiders | |
|---|---|
| Johan Rutger Christenson | 35 |
| Catherine Moukheibir | 29 |
| Jean-Pierre Garnier | 28 |
| Mary L. Campbell | 27 |
| Michael Davidson | 27 |
| Denis Lucquin | 26 |
| Olivier Martinez | 19 |
| Marc Rivière | 18 |
| Christian Chavy | 18 |
| Richard Pasternak | 16 |
| Alexandra Goll | 14 |
| Barbara Yanni | 13 |
| Daniela Oniciu | 8 |
| Narendra D. Lalwani | 8 |
| Jean-Louis Dasseux | 8 |
- Bourse
- Insiders
- Cyrille Tupin
- Connexions Sociétés
